knowledge -WSS

knowledge

author：explore 2025-09-03 11:20:51 - browse：92594

Boxes of Wegovy — pharma coverage from STAT — Carsten Snejbjerg/Bloomberg

LONDON — The investment arm of Novo Nordisk’s parent foundation is buying drug manufacturer Catalent in a $16.5 billion deal, an acquisition that will give Novo additional sites as it builds up production of its booming obesity and diabetes drugs.

Under the deal, Novo Holdings is purchasing Catalent, a major contract development and manufacturing company with more than 50 sites globally. In turn, Novo Nordisk is buying three of Catalent’s fill-finish sites from the investment group for $11 billion. Novo Holdings manages the assets of the Novo Nordisk Foundation, which has a controlling stake in the pharmaceutical company.

Catalent has been involved in the production of Novo’s obesity treatment Wegovy. With the agreement, Novo will pick up sites that focus on filling drugs in Italy, Brussels, and Bloomington, Ind. All have already been doing work for Novo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Key House panel plots a new health care package

explore

focus

WSS

STAT Virtual Event: The State of Biosimilars: What to Watch

Biden's Plan B on student loan forgiveness relies on Higher Education Act: What to know

'Insanity': 4th of July mass shootings across US kill 13, injure more than 80

Man with guns arrested near Obama home 'attempted to evade' Secret Service: Prosecutors

Doctors find melanoma drugs effective against rare brain cancer

The leaders of Italy and Poland say European Union should focus on stopping migration

explore

knowledge

focus

New air purifier tech could be key to improving indoor air quality

Rescued Australian man who was adrift 3 months in Pacific with dog 'grateful' to be alive

Alkermes shareholders re

Condition critical? Britain's beloved but battered National Health Service turns 75

Bright Health sells Medicare Advantage business to Molina

How Medicaid coverage policies for immigrants impact new moms

DIEP, the 'gold standard' of breast reconstruction, is under threat

As digital health tech proliferates, a new institute aims to cut through hype

Novavax promises a turnaround & Lilly roils the obesity market

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

focus

Group opposing PBM reform sets lobbying record

Following judge's order, DOJ releases slightly less

Following judge's order, DOJ releases slightly less

Philadelphia mass shooting: Few answers in apparently random attack as suspect charged with murder

A bus careens into a gulch in southern Mexico, leaving 27 people dead

Supreme Court shows surprising restraint in chaotic year of crises: ANALYSIS

explore

focus

hotspot

knowledge